This interview was part of Dr Heather Sandison’s Reverse Alzheimer’s Summit. We discuss the Alzheimer’s disease risk biomarkers seen on magnetic resonance imaging studies and how they are not always limited to the brain.

 #longevity #wellness  #Ketones #lifestylemedicine #younger #ketosis #biohacking #acetone #RobertLufkinMD #rapamycin #metabolic #metabolism #Alzheimersdisease #MRI

***Rapamycin Longevity Registry***

https://www.rapamycin.io/

*** CONNECT WITH ROBERT LUFKIN MD ON SOCIAL MEDIA ***

Web: https://robertlufkinmd.com/ 

Twitter:https://twitter.com/robertlufkinmd

Youtube: https://www.youtube.com/RobertLufkinMD

*** MEMBERSHIP ***

https://robert-lufkin.mykajabi.com/membership 

*** SPONSORSHIPS & BRANDS ***

We do work with sponsors and brands. If you are interested in working with us for your health industry product or service, please contact us at: https://robertlufkinmd.com/contact 

 

NOTE: This is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have. Never disregard professional medical advice or delay in seeking it because of something you have seen here. 

Robert Lufkin MD may at any time and at its sole discretion change or replace the information available on this channel. To the extent permitted by mandatory law, Robert Lufkin MD shall not be liable for any direct, incidental, consequential, indirect or punitive damages arising out of access to or use of any content available on this channel, including viruses, regardless of the accuracy or completeness of any such content.

Disclaimer: We are ambassadors or affiliates for many of the brands we reference on the channel.

Robert Lufkin  0:01  
Welcome back to The HAL phone activity Secret show and I’m your host, Dr. Robert Lufkin. This interview was part of Dr. Heather Sandersons reverse Alzheimer’s summit from this fall, we discussed the Alzheimer’s disease risk biomarkers that are seen on magnetic resonance imaging studies and how they are not always limited to the brain.

Before we start the episode, if you like what you hear, please consider supporting the work we do as well as joining us on your personal health longevity journey. You can do both by becoming a member of our community. The benefits include a private messaging area, live QA sessions, weekly premier videos, product discounts, free giveaways, and much more. You can join for as little as $1 per month and the first month is free. See the link in the show notes for more information. And now Dr. Heather Sanderson and yours truly.

Heather Sandison  1:13  
Welcome to the reverse Alzheimer’s Summit. I’m your host, Dr. Heather Sanderson and I’m so excited to have Dr. Rob Lufkin here today. He’s a full professor at a leading medical school and chief of Neurology at a large medical network in Southern California. In addition to being a practicing physician, he is author of over 200 peer reviewed scientific papers, 32 book chapters and 13 books that are available in six languages. Dr. Lufkin is good at getting the word out. He is also hosting a prevention and Alzheimer’s prevention Summit. And so he and I share a lot of the same passions, and you know, goals for making Alzheimer’s a rare disease. Dr. Left, Ken, thank you so much for taking the time to join us today.

Unknown Speaker  1:59  
Oh, it’s great to be here. Heather, I’m really excited about participating in your Summit. And I can’t wait to hear the other speakers too. I’m really looking forward to it.

Heather Sandison  2:08  
Thank you. And thank you also it Dr. Lufkin and I are collaborating on some science and research that we’re both in Southern California. And so we feel very, very fortunate to be able to send some of our study participants up to get imaging from him. So he’s really is on the cutting edge of the research and science around getting the best imaging for Alzheimer’s patients and dementia patients. So I want to dive right in imaging is when part of our our workup and an Alzheimer’s patient because we can see not only the brain but other anatomy through the pictures that we take, as they say a picture’s teletype, a picture says 1000 words. And so I want to understand more about what imaging can and can’t do. Can we rule Alzheimer’s in or out based on a picture of the brain?

Unknown Speaker  2:57  
Okay, yeah, that’s a very, very good question. Because anytime we do any imaging study, and my background is, as you mentioned, I’m a neuro radiologist so that I specialize in imaging, and that’s what I do all day. But anytime we do an imaging study for a patient, it’s important to consider the question and why we’re doing it. So for example, a patient with who comes in with new cognitive impairment, and we’re trying to diagnose what might be the cause of that. There are a number of conditions that are rapidly treatable, some are even emergencies that can cause cognitive impairment. So the very first thing with a patient with cognitive impairment is to do an imaging study that will exclude immediately treatable causes of dementia and cognitive impairment. So that can either be a CT scan or an MRI scan. Either one of those allows us to look at the brain and find treatable things like a if the patient was involved in an accident, they may have a bleed in the brain something called the hematoma where blood accumulates and pushes on the brain gradually, and that can with the increased pressure will cause cognitive impairment that will occur over over a short period of time, but that’s something that can be treated with a with a drill hole in the brain by a neurosurgeon and, and the patient’s completely resolved. Other causes of cognitive impairment in the brain also can be recognized thanks like a brain tumors, like a glioblastoma or meningioma. These grow more slowly, and the cognitive impairment can come on over a much more gradual period. But again, these are things that can be addressed with surgery or other types of treatment, and the treating the tumor will in most cases, treat the cognitive impairment as well. So first thing we want to do is exclude all those immediately treatable conditions. Then once we’ve done that, then the next thing is to look at the look at the brain and look at the other causes of dementia that may not be immediately treatable, but it’s important to recognize them because they may be slightly different than Alzheimer’s disease. So the types of long term treatment or lifestyle modifications that we make for them may be slightly different.

Heather Sandison  5:30  
So when we are talking about Alzheimer’s, that one of the things that we’ve talked a lot of the others summit interviewees about is that it’s not always one thing. And oxygen, especially at night airway is a really, really big piece of one of the big contributors to cognitive decline. And so you have shared with me that you can actually see, when you do these MRI studies, you can actually see part of the airway and get a lot of great information about that as well. Can you can you speak to how you’re doing that?

Unknown Speaker  6:03  
Sure, absolutely. And that’s one of the very exciting things about Alzheimer’s disease, because, you know, for many years, there was the amyloid hypothesis for Alzheimer’s disease. And still many investigators are looking for a single drug that will somehow work on that. There’s now growing and very compelling evidence that Alzheimer’s disease may be based on have a multifactorial origin, things like it can involve airway problems, it can involve insulin resistance, inflammation, metabolic syndrome, trauma history, as well as toxins, which I’m sure your other speakers have been, have been addressing. But to the point about imaging studies, with within Mr. scan of the brain, were able not only to look at images of the brain itself and identify specific biomarkers for Alzheimer’s disease that we can talk about. But as you as you asked about, we can also see other areas on that image of the brain, which covers essentially from the neck, up through the top of the head, which includes the brain, but we also get a view to your point of the airway. So we can look for signs anatomically that would predispose for obstructive sleep apnea, which, you know, sleep disorders are a huge risk factor for Alzheimer’s disease and, and that can be done as part of the the Mr. imaging of the Alzheimer’s of the brain Alzheimer’s study.

Heather Sandison  7:44  
So I want to go into that you mentioned other biomarkers of Alzheimer’s that would be readily sort of visible on these pictures that you’re getting, what are they?

Unknown Speaker  7:52  
Okay, well, the, the classic biomarker for Alzheimer’s disease is atrophy in a part of the brain, that is the basis for memory and that is the hippocampus and and the hippocampus is a bilateral structure. And studies have shown that in patients with Alzheimer’s disease, not all of them, but a significant portion of them will show hippocampal atrophy or loss atrophy, meaning loss of volume of that structure. And the interesting thing about it that that really surprised a lot of people when this was just discovered a few years ago was the hippocampal atrophy can happen before any sign of cognitive impairment which is the usual usual thing that that brings a patient to the doctor and thinking they have Alzheimer’s disease, the this hippocampal atrophy can occur 10 or 20 years before the onset of cognitive impairment, this creates a great window for therapy especially these lifestyle interventions and other things that can be done because researchers have shown that the earlier these things are started these therapeutic interventions the more successful they are. So if you can wait before you have any cognitive impairment at all and and begin these things, these treatments, then you can you can have much better results than if you wait until the brain is actually damaged and and the and the memory occurs. So the hippocampal atrophy is the key finding and many people are now recommending in patients who have risk factors for Alzheimer’s disease such as the AOE for carrier state in the gene, or else if they have a family history of Alzheimer’s disease, that it’s worthwhile. Going back 20 years from the date of the onset of your Alzheimer’s disease in your in your relative For example, you know, God forbid, if you’re, if your parent had Alzheimer’s disease and it arrived, it began at age 70, then it’s probably worthwhile at age 50, to begin thinking about evaluating risk factors in yourself for possible Alzheimer’s disease, because we’re already seeing the changes starting to occur. And that’s when ideally you would start the lifestyle management and the treatment to make it better. So So hippocampal atrophy is the is really the key finding for Alzheimer’s disease. But there are a bunch of other biomarkers that we can see on the scan if you’d like I can, I can talk about those if you want to share. Yeah, so in addition to the hippocampal atrophy, we can also see evidence of vascular disease in the brain, which Alzheimer’s disease and vascular causes of dementia are the two main causes of dementia. So there there are classic findings of vascular changes in the brain that can be recognized on an MRI scan. And quite honestly, vascular dementia overlaps with Alzheimer’s disease. So it’s it’s not a clear finding there but you can you can find the vascular disease signature as well. Going outside of the brain, in addition to the hippocampus and the vascular structures, we can look at the airway, as we already mentioned, looking for signs of obstructive sleep apnea, and that can then indicate the patient might benefit from a sleep study or, or looking at their blood oxygenation, while they sleep and doing that. Other things we can look at are the sinuses. So interesting chronic sinus disease is an independent risk factor for Alzheimer’s dementia and treating patients sinus disease has have improved the cognitive impairments in these patients it’s it’s interesting to think that the that the sinuses are separate from the brain yet they can have the effects but if we think about inflammation, we think about some of these other factors that we know now cause Alzheimer’s disease it it all sort of makes sense. So the sinuses can be beautifully evaluated on the MR imaging study. And it’s important to note that patients can have sinus disease visible on the EMR without symptoms. So these can it can be asymptomatic and it’s just there and possibly contributing to their Alzheimer’s disease, but they’re not even aware of it because they don’t have symptoms of sinusitis. When we’re looking at the sinuses on the MR scan, another thing that we can look at specifically is their specific hallmarks of fungal sinus disease, which is a particularly troublesome biomarker for Alzheimer’s. Fungal infections at various locations in the body can can contribute to risk for Alzheimer’s disease. So there are specific imaging findings of the sinuses that indicate a fungal sinus infection and the Mr. Scan can pick that up and like conventional chronic sinusitis, this fungal sinusitis may be clinically silent also, in other words, the patient may not be aware that they that they even have it. So, in addition to the sinuses and the brain structures, if we go down one step lower, the scan will also include the teeth, the the mandible, the maxilla, and all the dentition. And, as as we’re learning now, inflammation in the teeth, interestingly, can Prease predispose a patient to a risk for a heart attack, but also for Alzheimer’s disease. So you don’t want to get Alzheimer’s disease brush your teeth every day. The the things on the scans that we can look at the markers for teeth is we can see periodontal disease we can see and a Donald disease that in some cases may be clinically silent that the patient may not be aware of but we can also detect abnormalities of the teeth and then you know suggest that they they might benefit from a from a thorough dental exam as well. On the on the scans the the MRI scan is also very sensitive to metal, it’s just detects it distorts the magnetic field when the images are obtained. So, metal anywhere in the head and neck area will show up on the scan. So, patient may have had surgery in the past and they may not even remember that metal was put in or they may not know it or they may have you know dental work with with metal embedded and while a good good dentist should be able to see it with EMR we can we can immediately detect metal and at least raise the possibility that that metal is there and and some researcher some researchers are even advocating removal of certain types of metals that may contribute more to Alzheimer’s. Disease in addition to the sinuses, the brain, the airway and the T. The other area we can look is

Unknown Speaker  15:11  
just the overall facial structure of the bones and the skull. Trauma is a risk factor and independent risk factor for Alzheimer’s disease and it may not be it may not be immediate trauma that the patient even remembers that may have been something that occurred 1020 years ago, we’re even seeing you know, a career in high school football with relatively minor head injuries even know concussions or loss of consciousness may contribute and and is a known risk factor for dementia later on in life. So the the imaging studies in some cases will provide evidence of trauma such as a nasal bone fracture, or facial fractures, that the pain forgotten or, you know, doesn’t remember anymore that they occurred. And so it can basically begin the conversation with the patient about about the history of trauma. And, and also if, depending on what their lifestyle is, or their current employment, they may want to be counseled about, you know, not being in a position where they have continued head trauma if they’re at a risk for Alzheimer’s disease or have other biomarkers.

Heather Sandison  16:26  
So as our listeners, and viewers may imagine, when I heard that we could get all of this from one image, I was ecstatic. I mean, this changes the game, because so many patients will ask a little bit about, you know, their dental history, or did you ever hurt your head and as you mentioned, so many times, these things are not showing up clinically, patients will not complain of a toothache, or even remember that they hit their head. And so they’re not, they’re not always making the connections that can often be there. And being able to roll these and roll these out, or at least consider them is really, really, really important. So of course, I was thrilled when you told me that you do this. And my next question was, well, can everyone get this? Do they need contrast? You know, how long does it take? What if they’re claustrophobic and they can’t get in the MRI machine? How long do they need to be in there for, you know, what are some of these these barriers to entry, it doesn’t transport covered, I can certainly speak from a clinician standpoint that I’ve done neuro quantitative volume metrics. And the information I get is very simply different. How big are the different regions of the brain, including the big campus, but it really doesn’t go beyond that. It’s not looking at airway, which we know is so important. It’s not looking at bones, it’s not looking at the sinuses, as you’ve mentioned. So you are unique in in terms of Radiology, as a radiologist that you are considering all of these things. So I want our listeners to know how they can access your interpretation of these pictures.

Unknown Speaker  17:58  
Yeah, just just to be clear, yeah, all the information is on the scan, but many radiologists based on their training, if they’re if they’re not focusing on Alzheimer’s disease or don’t have an interest in it necessarily. The average radiologist doesn’t pay attention to the airway and and may not, may not make an effort to comment on some of the other areas that I mentioned. So I I’m very excited about Alzheimer’s disease and the possibility of how this can help people. Maybe all later on, I’ll give you some information about a website that we’re setting up that they could send us the scans for that we can put that in in the show notes if you want. Specifically, the questions you asked is very good about what are the barriers for these types of studies and everything because the great thing about Mr. Magnetic wrist and it’s other than things like CT scans, Computed Tomography or PET scanning, which have been in our use for Alzheimer’s disease. The problem with these is those two types in particular, they when they’re expensive, and they also use radiation. You know, as as your listeners probably may know, any exposure to radiation, X radiation from a CT scan or PET scan raises the possibility of developing cancers later on in your life. So it limits the ability to do repeat scans for follow up. And the great thing about magnetic resonance is there’s no x rays, there’s no ionizing radiation, so there’s no known harm to the patient. The other thing that we’re working on is coming up with a tailored Mr. scan that is relatively inexpensive. That omits a lot of the unnecessary things and that’s unnecessary charges. so that it would be something that would be affordable that the patient could actually have done more than once and even as a follow up to monitor their treatment, because amazingly, even things like brain atrophy and the hippocampus have has been shown to be reversible wide by lifestyle and other treatments, in as short a time as six months. So this would be a tremendous driving factor for the patient to be able to see, I’m actually fixing my brain and fixing the part of the brain that controls memory. And I can see it on this follow up scan that I do, and maybe a year or something like that. And of course, the airway in the sinuses would also you could see the improvement there. So the the great thing about magnetic resonance is that it there’s no radiation with it, we’re keeping the costs down very low with this with this limited, very limited scan. And then also there is no injection, you asked about contrast material, which usually involves putting a catheter or a needle into a vein and then injecting things. We don’t do any of that with the Mr. Scan. So it’s it’s completely non invasive I even having my 12 year old daughter doing to look at her brain for a science project. But so it’s it’s an ideal imaging study for this for this type of evaluation.

Heather Sandison  21:30  
Yeah, when you mentioned that somebody should be looking at this 20 years before the onset of symptoms. That’s exactly what I started wondering, well, if, if we’re measuring hippocampal volume, that area of the brain that’s so associated with memory? And if we measure it, when someone’s already got symptoms, how do we know if maybe they’re not just there, they maybe were born with a little bit smaller Hippocampus on the, you know, the curve, the standard deviation? And so what if that’s part of what’s going on? If we don’t have a baseline from before when they had symptoms, then we don’t really know what’s caused it. And so yeah, I’m just curious if in an ideal world, how often would somebody who has risk factors be getting one of these images?

Unknown Speaker  22:12  
Okay, that’s a very, very good question. And this, this technology is literally just developed in the last 10 years or so. It’s involving large amounts of computing power. And actually, it involves deep learning and artificial intelligence with the convolutional neural networks that everyone’s talking about. But to your point about, how do we know if the hippocampal volume is not some pre existing thing, or how do we know it’s even abnormal? Well, the first thing that is done when the these volumes, the spring volumes are calculated, the patient gets an MRI scan of their head. And the first thing you do is we measure the size of the head on the scan, and I may have a big head. But, and my hippocampus will be big, or I may have a very small head and my hippocampus will be small. So we need to account for that. So the first thing we do is we we take the size of their B, we either shrink it or we enlarge it to a normal, a normal Atlas, sort of a normal volume. But that’s that’s really not enough, because the hippocampus changes in size with aging, it gets bigger as you’re younger, and then it gets smaller as you get older. And those changes actually are different in men and women. So both of those things have to be taken into account. So in addition to the shrinking or expanding the head to the normal Atlas, then the next thing we do is we we map it onto an age matched and gender matched normal Atlas for that person. So we look at a 50 year old man, and we we compare it with that. So that does that that does the comparison. But your point about follow up scans is very important. Because if I do one scan, and my hippocampal volume is let’s say it’s low normal, it’s still normal, but it’s it’s low normal, I could still be at risk for Alzheimer’s disease, because six months ago or a year ago, it may have been high normal, but from that single study, it’s still within the normal range. So the real advantage and many investigators are advocating this is it’s not a single scan, but it’s a change over time. So do a repeat scan in one year. And I could be low normal, the first scan and then the second scan. I could be very low normal but still normal. But the fact that it has a downward trajectory is very concerning. And that in effect is the positive biomarker for Alzheimer’s disease. So having at least two scans is valuable to assess the essentially the veloce To the of the change rather than a static point in time,

Heather Sandison  25:03  
right, that change over time is what’s more important than even maybe that number itself. And that that number is normalized, you know, so that we know what is normal and what’s not your age, your sex, and hopefully compared to previous because it does sound like a baseline would be very, very helpful, particularly if you have high genetic risk, or other factors.

Unknown Speaker  25:26  
And it’s been shown that people who are a PL E for homozygous, which means they have both alleles, or a bo E for they genetically have smaller hippocampal volumes than do normal people. And we’re still trying to, we’re still gathering data and understanding. If they increase their hippocampal volume, what that does the risk and and, and as you might expect, the the homozygous AP fours have a smaller volume that heterozygous with one AP four and one AP AP three or two, have a have a slightly larger hippocampal volume. But work is being done on this and with more and more experience, we’ll hopefully be able to understand this better and make better recommendations for people trying to manage their risk.

Heather Sandison  26:21  
That’s fascinating. Yes, I’m excited to collaborate and questions. I’m curious if you could design any study, you were working on some research together, if you could design any study and answer any questions, there’s no, there’s no constraints, financial or otherwise, you have all the participants you want. And all of the money you need to finish it. What what question, would you ask, what would what is the burning question in your mind? We don’t know about the subject yet?

Unknown Speaker  26:49  
Well, I think the the real exciting question for me is the ones that many investigators are beginning to address like like Dale Bredesen and the work that you’re doing and in your clinic, and that is how these how these long term risk factors can contribute to Alzheimer’s disease and how how we can how we can manage the risk factors through lifestyle changes and other other management and thus prevent developing Alzheimer’s disease later on. And the tools that I would offer for that would be imaging to take a look at the brain and the other areas and just do it as inexpensively as possible to make it affordable. And of course with no radiation. I think one of the questions you asked about insurance payment for these in this varies according to insurance companies and varies according to different things. But my general experience is if the patient has a diagnosis of cognitive impairment or dementia significant clinical findings there that most insurance companies and Medicare will pay for an imaging study, at least one imaging study, like we talked about earlier to rule out other immediately treatable causes of dementia. It’s been my experience, they won’t pay necessarily for follow up ones unless the patient changes unless something happens that they really change their their pattern that way, but and then, as far as prevention, patients who don’t have any cognitive impairment yet, but let’s say they have a family member who developed it, or they’re a belief for positive. It’s been my experience that the insurance companies won’t cover imaging studies for this, which is, which is really sad. Because just from a financial perspective, Alzheimer’s, the disease is incredibly expensive in the health care system. I mean, just aside from the cost to the families and everything, but the financial costs are very high, you’d be much better off beginning lifestyle management and changes early on and preventing Alzheimer’s disease than waiting till people actually have cognitive impairment, which, as we’ve said, is really a late finding and Alzheimer’s disease, although it’s for most people, the first finding that they that they detect to acknowledge they even have it.

Heather Sandison  29:28  
It really is so heartbreaking that I think you and I now are we feel strongly that this is preventable, that there are interventions you can take we can we can get the information early enough that we can prevent Alzheimer’s and even reverse it. We’re seeing lots of that in my clinic. And I think we want to share that information and what you were doing creates so much hope and so you seen that picture. I think it’s really really really valuable. We can talk about last time URL changes, and we can talk about the genetics. And I think they tend to be a little nebulous for going there. It’s not as it’s not as tangible as seeing a picture of their brain and going, Wow, that is shrinking, and I got to do something about it. So I think in a very real way, you give people not only the the motivation they need, but also the hope that these things can change that you’ve watched the images change, that you’ve watched the symptoms change, that you’ve seen people do this successfully, and that there is a way to avoid this heartbreak, like you described, you know, it’s it, Alzheimer’s is so destructive financially, but also, it robs us of this generation that has so much wisdom, and it’s so much to offer us, it’s almost in my mind, it’s the squandered resource, right? The the height of their wisdom and experience, our elders are being removed from society because of dementia. That is, yes. For doing the work that you’re doing.

Unknown Speaker  31:00  
Oh, well, thanks. It is such an exciting area. And the changes that are happening now with the possibility of treatment, which wasn’t there a few years ago, the possibility of prevention that was there a few years ago, the work you’re doing in your clinic, the work that researchers like Dale Bredesen and others are doing it’s really revolutionary and, and it’s so exciting to be involved with this and to try and get the message out to help as many people as we can.

Heather Sandison  31:30  
Yeah, very, very hopeful and exciting time. Thank you. Again. Dr. Lufkin. It’s just an absolute pleasure not only to get to have these conversations with you to get to share them, but also to be collaborating in other ways to advance this field and give more and more families hope and an answer so that they don’t have to suffer

Unknown Speaker  31:48  
greatly. Thanks a lot, Heather, and really looking forward to your summit and hearing the other speakers it’s going to be very exciting.

Heather Sandison  31:56  
Can you give our listeners and you have ProHealth? Is your your business? Is there a website or other places where they can find out more information about what you

Unknown Speaker  32:07  
find could if I could pass it to you afterwards in the show notes if that’s possible website that they can go to and get more information. We’re just putting it together now.

Heather Sandison  32:20  
Perfect, wonderful. We’ll have that in the show notes.

Unknown Speaker  32:23  
No, this is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have. Never disregard professional medical advice or delay in seeking of it because of something you’ve seen here. If you find this to be a value of you, please hit that like button and subscribe and support the work we do on this channel. Also, we take your suggestions and advice very seriously. Please let us know what you’d like to see on this channel. Thanks for watching and hope to see you next time.